Can you provide the last earnings date for APELLIS PHARMACEUTICALS INC?
APELLIS PHARMACEUTICALS INC (APLS) last reported earnings on 2/24/2026.
NASDAQ:APLS • US03753U1060
Past quarterly earnings results for APELLIS PHARMACEUTICALS INC (APLS), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | -0.47 | -0.39 | -21.01% | -62.07% | 199.913M | 203.7M | -1.86% | -5.94% |
| Q3 2025 | 1.67 | 1.21 | 38.10% | 463.04% | 458.578M | 414.81M | 10.55% | 132.98% |
| Q2 2025 | -0.33 | -0.48 | 31.03% | -17.86% | 178.494M | 192.29M | -7.17% | -10.61% |
| Q1 2025 | -0.74 | -0.37 | -101.36% | -76.19% | 166.797M | 199.52M | -16.40% | -3.21% |
| Q4 2024 | -0.29 | -0.39 | 26.26% | 60.27% | 212.528M | 202.32M | 5.05% | 45.19% |
| Q3 2024 | -0.46 | -0.31 | -50.27% | 60.68% | 196.83M | 204.36M | -3.68% | 78.29% |
| Q2 2024 | -0.28 | -0.33 | 15.16% | 72.55% | 199.685M | 194.9M | 2.46% | 110.26% |
| Q1 2024 | -0.42 | -0.48 | 11.77% | 73.08% | 172.325M | 166.62M | 3.42% | 284.26% |
| Q4 2023 | -0.73 | -0.70 | -4.28% | 51.33% | 146.377M | 146.47M | -0.06% | 544.83% |
| Q3 2023 | -1.17 | -0.87 | -34.09% | 33.14% | 110.399M | 101.04M | 9.26% | 399.54% |
| Q2 2023 | -1.02 | -1.35 | 24.40% | 30.14% | 94.969M | 71.657M | 32.53% | 482.63% |
| Q1 2023 | -1.56 | -1.49 | -4.46% | -9.86% | 44.846M | 26.625M | 68.44% | 211.43% |
| Q4 2022 | -1.50 | -1.60 | 6.20% | 6.83% | 22.7M | 24.921M | -8.91% | -62.35% |
| Q3 2022 | -1.75 | -1.48 | -17.99% | 23.25% | 22.1M | 22.025M | 0.34% | 287.72% |
| Q2 2022 | -1.46 | -1.39 | -4.87% | 46.32% | 16.3M | 17.283M | -5.69% | 2,616.67% |
| Q1 2022 | -1.42 | -1.35 | -5.49% | 38.79% | 14.4M | 12.824M | 12.29% | - |
| Q4 2021 | -1.61 | -1.57 | -2.63% | -273.12% | 60.3M | 8.96M | 572.99% | -75.88% |
| Q3 2021 | -2.28 | -1.73 | -31.79% | -27.37% | 5.7M | 7.37M | -22.66% | 850.00% |
| Q2 2021 | -2.72 | -1.72 | -58.19% | -73.25% | 600K | 509.918K | 17.67% | - |
| Q1 2021 | -2.32 | -1.62 | -43.34% | -1.31% | 2.318M | -100.00% | - | |
| Q4 2020 | 0.93 | -0.77 | 221.15% | - | 250M | 98.008M | 155.08% | - |
| Q3 2020 | -1.79 | -1.61 | -11.07% | - | 600K | - | - | |
| Q2 2020 | -1.57 | -1.36 | -15.26% | - | - | - | ||
| Q1 2020 | -2.29 | -1.41 | -62.50% | - | - | - |
Notes
APELLIS PHARMACEUTICALS INC (APLS) last reported earnings on 2/24/2026.
APELLIS PHARMACEUTICALS INC (APLS) missed EPS estimates and missed revenue estimates in the most recent quarter.
In the last 4 quarters, APELLIS PHARMACEUTICALS INC (APLS) has beaten EPS estimates in 2 out of 4 releases.